Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 125

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 125
---
 we obtain all necessary FDA approvals,
our product candidates may not achieve or maintain market acceptance.

Even if we obtain
FDA approval of our product candidates, market acceptance of our products in the healthcare community, including among physicians, patients
and third-party payors, will depend on many factors, including:

| ● | our ability to provide incremental clinical and economic data demonstrating the safety, clinical efficacy                                
 and cost-effectiveness of, and patient benefit from, our products, and any perceived inadequacy of evidence supporting clinical benefits 
 or cost-effectiveness over existing alternatives;                                                                                        |

| ● | the availability of alternative treatments; |

| ● | whether our products are included on insurance company formularies or coverage plans; |

| ● | the willingness and ability of patients and the healthcare community to adopt new technologies; |

| ● | customer demand; |

| ● | liability risks generally associated with the use of new product candidates; |

| ● | the training required to use a new product candidate; |

| ● | the convenience and ease of use of our products relative to other treatment methods; |

| ● | the pricing and reimbursement of our products relative to other treatment methods; and |

| ● | the marketing and distribution support for our products. |

Therefore, even
if we obtain all necessary FDA approvals, our products may fail to achieve market acceptance. If our products achieve market acceptance,
they may not maintain that market acceptance over time if competing products or technologies are introduced that are received more favorably
or are more cost-effective. Failure to achieve or maintain market acceptance would limit our ability to generate revenue and would have
a material adverse effect on our business, financial condition, results of operations and prospects.

| 50 |

We may be unable to compete
successfully with larger companies in our highly competitive industry.

The medical technology
and pharmaceutical industries are highly competitive and the medical device industry is characterized by rapid and significant change.
Many of our current and potential competitors have substantially greater financial, manufacturing, marketing and technical resources than
we do. Larger competitors may have substantially larger sales and marketing operations than we or our partners have or plan to have and
may have greater name recognition. This may allow those competitors to spend more time with potential customers and to focus on a larger
number of potential customers, which would give them a significant advantage over the sales and marketing team we would use and our international
distributors in making sales.

Larger competitors
may also have broader product lines, which enable them to offer customers bundled purchase contracts and quantity discounts.